Skip to Content

Altimmune to Participate at the Noble Capital 14th Annual Investor Conference

Jan 22, 2018

GAITHERSBURG, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference, being held January 29-30, 2018 at the W Hotel, Fort Lauderdale, Florida.

14th Annual Investor Conference Presentation Details
Date:       Tuesday, January 30, 2018
Time:       2:30pm Eastern Time
Location:       W Hotel, Ft. Lauderdale, Florida, Studio 2

A high-definition, video webcast of the presentation will be available the following day on the Company's web site and as part of a complete catalog of presentations available at Noble Capital Markets’ websites:, and You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.

About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

Bill Enright 
President and CEO
Phone: 240-654-1450

Ashley Robinson
Managing Director LifeSci Advisor
Phone: 617-535-7742


Primary Logo


Source: Altimmune, Inc.